Meditor Group Discloses 3.3% Passive Stake in Esperion Therapeutics
Ticker: ESPR · Form: SC 13G/A · Filed: Jan 3, 2024 · CIK: 1434868
| Field | Detail |
|---|---|
| Company | Esperion Therapeutics, Inc. (ESPR) |
| Form Type | SC 13G/A |
| Filed Date | Jan 3, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, stake-update
TL;DR
**Meditor Group holds 3.3% of Esperion Therapeutics, a passive but notable stake.**
AI Summary
Meditor Group Ltd. and Meditor European Master Fund Ltd., both based in Bermuda, have updated their ownership stake in Esperion Therapeutics, Inc. As of December 31, 2023, they collectively beneficially own 3,791,300 shares of Esperion's common stock, representing 3.3% of the company's outstanding shares. This filing indicates a passive investment, meaning Meditor is not seeking to influence management, but it's important for investors to know that a significant institutional holder has a notable, albeit slightly reduced, position in the company.
Why It Matters
This filing shows that a significant institutional investor, Meditor Group, maintains a substantial, though passive, stake in Esperion Therapeutics, which can influence market perception and liquidity.
Risk Assessment
Risk Level: low — This is a routine update on an institutional ownership stake and does not indicate any immediate financial risk or operational change for Esperion Therapeutics.
Analyst Insight
An investor should note that a significant institutional holder, Meditor Group, maintains a 3.3% stake in Esperion Therapeutics, indicating continued, albeit passive, institutional interest. This information can be factored into an assessment of institutional confidence, but it doesn't suggest any immediate catalyst for price movement or corporate action.
Key Numbers
- 3,791,300 — Shares Beneficially Owned (This is the total number of Esperion Therapeutics shares Meditor Group Ltd. and Meditor European Master Fund Ltd. jointly own.)
- 3.3% — Percentage of Class (This represents the portion of Esperion Therapeutics' common stock owned by Meditor Group, indicating a significant institutional holding.)
- December 31, 2023 — Reporting Date (This is the snapshot date for the ownership information, providing the most recent reported stake.)
Key Players & Entities
- Meditor Group Ltd. (company) — reporting person, beneficial owner of Esperion Therapeutics shares
- Meditor European Master Fund Ltd. (company) — reporting person, beneficial owner of Esperion Therapeutics shares
- Esperion Therapeutics, Inc. (company) — the issuer whose securities are being reported
- 3,791,300 (dollar_amount) — number of shares beneficially owned by each reporting person
- 3.3% (dollar_amount) — percentage of class represented by the aggregate amount beneficially owned
- December 31, 2023 (date) — date of event which requires filing of this statement
Forward-Looking Statements
- Meditor Group will maintain a passive investment strategy in Esperion Therapeutics for the foreseeable future. (Meditor Group Ltd.) — high confidence, target: 2025-12-31
- The 3.3% stake held by Meditor Group will not lead to immediate activist pressure on Esperion Therapeutics' management. (Esperion Therapeutics, Inc.) — high confidence, target: 2024-12-31
FAQ
Who are the reporting persons in this SC 13G/A filing?
The reporting persons are Meditor Group Ltd. and Meditor European Master Fund Ltd., both organized in Bermuda, as stated in Item 1 of the filing.
What is the total number of Esperion Therapeutics, Inc. shares beneficially owned by the reporting persons?
As of December 31, 2023, both Meditor Group Ltd. and Meditor European Master Fund Ltd. each beneficially own 3,791,300 shares of Esperion Therapeutics, Inc. common stock, as detailed in Row 9 of the filing.
What percentage of Esperion Therapeutics, Inc.'s common stock do the reporting persons collectively own?
The reporting persons collectively own 3.3% of Esperion Therapeutics, Inc.'s common stock, as indicated in Row 11 of the filing for both Meditor Group Ltd. and Meditor European Master Fund Ltd.
What is the CUSIP number for Esperion Therapeutics, Inc. common stock mentioned in the filing?
The CUSIP number for Esperion Therapeutics, Inc. common stock is 29664W105, as stated in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(c), as indicated by the 'X' mark next to '[ X ]Rule 13d-1(c)' in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 3, 2024 regarding Esperion Therapeutics, Inc. (ESPR).